biostudies-literatureLisanby SHNIMH NIH HHSNational Institute of Mental Health15-28https://www.ebi.ac.uk/biostudies/studies/S-EPMC8595359biostudies-literatureUnknown30(1)<h4>Objective</h4>There is limited information regarding neurocognitive outcomes of right unilateral ultrabrief pulse width electroconvulsive therapy (RUL-UB ECT) combined with pharmacotherapy in older adults with major depressive disorder. We report longitudinal neurocognitive outcomes from Phase 2 of the Prolonging Remission in Depressed Elderly (PRIDE) study.<h4>Method</h4>After achieving remission with RUL-UB ECT and venlafaxine, older adults (≥60 years old) were randomized to receive symptom-titrated, algorithm-based longitudinal ECT (STABLE) plus pharmacotherapy (venlafaxine and lithium) or pharmacotherapy-only. A comprehensive neuropsychological battery was administered at baseline and throughout the 6-month treatment period. Statistical significance was defined as a p-value of lessThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric PsychiatryLongitudinal Neurocognitive Effects of Combined Electroconvulsive Therapy (ECT) and Pharmacotherapy in Major Depressive Disorder in Older Adults: Phase 2 of the PRIDE Study.PMC8595359U01 MH086127U01 MH081362U01 MH084241U01 MH086122U01 MH055495U01 MH086123U01 MH086130U01 MH086120Briggs MCCullum CMGeduldig ETKaliora SPrudic JDeng ZDRudorfer MVBailine SHKellner CHYoung RCTobias KGPetrides GKnapp RGMcCall WVBernhardt ESampson SLiebman LSGreenberg RMLatoussakis VWeiner RDLisanby SHTeklehaimanot AAMcClintock SMHusain MMMueller MRosenquist PBAlexopoulos GProlonging Remission in Depressed Elderly (PRIDE) Work GroupfalseLongitudinal Neurocognitive Effects of Combined Electroconvulsive Therapy (ECT) and Pharmacotherapy in Major Depressive Disorder in Older Adults: Phase 2 of the PRIDE Study.<h4>Objective</h4>There is limited information regarding neurocognitive outcomes of right unilateral ultrabrief pulse width electroconvulsive therapy (RUL-UB ECT) combined with pharmacotherapy in older adults with major depressive disorder. We report longitudinal neurocognitive outcomes from Phase 2 of the Prolonging Remission in Depressed Elderly (PRIDE) study.<h4>Method</h4>After achieving remission with RUL-UB ECT and venlafaxine, older adults (≥60 years old) were randomized to receive symptom-titrated, algorithm-based longitudinal ECT (STABLE) plus pharmacotherapy (venlafaxine and lithium) or pharmacotherapy-only. A comprehensive neuropsychological battery was administered at baseline and throughout the 6-month treatment period. Statistical significance was defined as a p-value of less2022-01-01T00:00:00Z2022 Jan2026-05-08T02:07:35.86Z2025-02-18T22:34:19.442ZS-EPMC85953593407461110.1016/j.jagp.2021.04.006